CMR FigSearch
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Koelle, D. M.
Right arrow Articles by Corey, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Koelle, D. M.
Right arrow Articles by Corey, L.

 Previous Article  |  Next Article 

Clinical Microbiology Reviews, January 2003, p. 96-113, Vol. 16, No. 1
0893-8512/03/$08.00+0     DOI: 10.1128/CMR.16.1.96-113.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Recent Progress in Herpes Simplex Virus Immunobiology and Vaccine Research

David M. Koelle1,2,3,4,5* and Lawrence Corey1,3,4

Departments of Medicine,1 Pathobiology,2 Laboratory Medicine, University of Washington, Seattle, Washington 98195,3 Fred Hutchinson Cancer Research Center, Seattle, Washington 98109,4 Virginia Mason Research Center, Seattle, Washington 981015

Herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) cause prevalent, chronic infections that have serious outcomes in some individuals. Neonatal herpes may occur when the infant traverses the cervix during maternal genital herpes. Genital herpes is a major risk factor for human immunodeficiency virus type 1 transmission. Considerable efforts have been made to design and test vaccines for HSV, focusing on genital infection with HSV-2. Several protein subunit vaccines based on HSV-2 envelope glycoproteins have reached advanced-phase clinical trials. These antigens were chosen because they are the targets of neutralizing-antibody responses and because they elicit cellular immunity. Encouraging results have been reported in studies of treatment of HSV-seronegative women with a vaccine consisting of truncated glycoprotein D of HSV-2 and a novel adjuvant. Because most sexual HSV transmission occurs during asymptomatic shedding, it is important to evaluate the impact of vaccination on HSV-2 infection, clinically apparent genital herpes, and HSV shedding among vaccine recipients who acquire infection. There are several other attractive formats, including subunit vaccines that target cellular immune responses, live attenuated virus strains, and mutant strains that undergo incomplete lytic replication. HSV vaccines have also been evaluated for the immunotherapy of established HSV infection.

* Corresponding author. Mailing address: Harborview Medical Center Mail Stop 359690, 325 Ninth Ave., Seattle, WA 98104. Phone: (206) 341-5207. Fax: (206) 341-5203. E-mail: viralimm{at}u.washington.edu.

Clinical Microbiology Reviews, January 2003, p. 96-113, Vol. 16, No. 1
0893-8512/03/$08.00+0     DOI: 10.1128/CMR.16.1.96-113.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Antimicrob. Agents Chemother. Clin. Vaccine Immunol.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2003 by the American Society for Microbiology. All rights reserved.